Iron Studies: Iron (Total), Iron-Binding Capacity (Total), Transferrin, and Iron Saturation
Iron: Fe; iron-binding capacity and iron saturation: TIBC, Fe Sat; transferrin: siderophilin, TRF.
To monitor and assess iron levels related to blood loss, dietary intake and metabolism, storage disorders, and replacement therapy. To assist in diagnosing types of anemia such as iron deficiency.
Instruct the patient to fast for at least 12 hr before specimen collection for iron or transferrin and, with medical direction, to refrain from taking iron-containing medicines before specimen collection. There are no food, fluid, activity, or medication restrictions unless by medical direction for the TIBC and iron saturation. Specimen collection for iron studies should be delayed for several days after blood transfusion. Protocols may vary among facilities.
Method: Spectrophotometry for iron and TIBC; nephelometry for transferrin.
|Age||Conventional Units||SI Units (Conventional Units × 0.179)|
|Newborn||100–250 mcg/dL||17.9–44.8 micromol/L|
|Infant–14 yr||40–105 mcg/dL||7.2–18.8 micromol/L|
|Male||75–175 mcg/dL||13.4–31.3 micromol/L|
|Female||60–160 mcg/dL||11–29 micromol/L|
|Values tend to decrease in older adults.|
|Test||Conventional Units||SI Units (Conventional Units × 0.179)|
|TIBC||250–450 mcg/dL||45–81 micromol/L|
|Transferrin-iron saturation %||15%–50%||15%–50%|
|The percentage of transferrin saturated with iron can be calculated as either (serum iron/TIBC value) × 100 or (serum iron × 100%)/TIBC.|
|Transferrin (Direct Measurement)|
|Age||Conventional Units||SI Units (Conventional Units × 0.01)|
|Newborn||130–275 mg/dL||1.3–2.75 g/L|
|Infant–14 yr||180–330 mg/dL||1.8–3.3 g/L|
|Male||215–365 mg/dL||2.2–3.6 g/L|
|Female||250–380 mg/dL||2.5–3.8 g/L|
Critical Findings and Potential Interventions
- Mild Toxicity: Greater than 350 mcg/dL (SI: Greater than 62.6 micromol/L)
- Serious Toxicity: Greater than 400 mcg/dL (SI: Greater than 71.6 micromol/L)
- Lethal: Greater than 1,000 mcg/dL (SI: Greater than 179 micromol/L)
Timely notification to the requesting health-care provider (HCP) of any critical findings and related symptoms is a role expectation of the professional nurse. A listing of these findings varies among facilities.
Intervention may include chelation therapy by administration of deferoxamine mesylate (Desferal).
There's more to see -- the rest of this topic is available only to subscribers.